Home Healthcare Healthcare Services Live Biotherapeutic Products And Microbiome CDMO Market

Live Biotherapeutic Products And Microbiome CDMO Market Size, Share & Trends Analysis Report By Component (Solution, Services), By Type (Bacterial LBPs, Viral LBPs, Fungal LBPs, Others), By Application (Gastrointestinal Disorders, Oncology, Neurological Disorders, Infectious Diseases, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: May 25, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Live Biotherapeutic Products And Microbiome CDMO Market, By Component 2022-2034 (USD MILLION/ Units)
    1. Solution
    2. Services
  2. Live Biotherapeutic Products And Microbiome CDMO Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Bacterial LBPs
    2. Viral LBPs
    3. Fungal LBPs
    4. Others
  3. Live Biotherapeutic Products And Microbiome CDMO Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Gastrointestinal Disorders
    2. Oncology
    3. Neurological Disorders
    4. Infectious Diseases
    5. Others
  4. Regional Live Biotherapeutic Products And Microbiome CDMO Market
    1. North America
      1. North America Live Biotherapeutic Products And Microbiome CDMO Market By Component 2022-2034 (USD MILLION/ Units)
        1. Solution
        2. Services
      2. North America Live Biotherapeutic Products And Microbiome CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Bacterial LBPs
        2. Viral LBPs
        3. Fungal LBPs
        4. Others
      3. North America Live Biotherapeutic Products And Microbiome CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gastrointestinal Disorders
        2. Oncology
        3. Neurological Disorders
        4. Infectious Diseases
        5. Others
      4. U.S.
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      5. Canada
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
    2. Europe
      1. Europe Live Biotherapeutic Products And Microbiome CDMO Market By Component 2022-2034 (USD MILLION/ Units)
        1. Solution
        2. Services
      2. Europe Live Biotherapeutic Products And Microbiome CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Bacterial LBPs
        2. Viral LBPs
        3. Fungal LBPs
        4. Others
      3. Europe Live Biotherapeutic Products And Microbiome CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gastrointestinal Disorders
        2. Oncology
        3. Neurological Disorders
        4. Infectious Diseases
        5. Others
      4. U.K.
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      5. Germany
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      6. France
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      7. Spain
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      8. Italy
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      9. Russia
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      10. Nordic
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      11. Benelux
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      12. Rest of Europe
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
    3. APAC
      1. APAC Live Biotherapeutic Products And Microbiome CDMO Market By Component 2022-2034 (USD MILLION/ Units)
        1. Solution
        2. Services
      2. APAC Live Biotherapeutic Products And Microbiome CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Bacterial LBPs
        2. Viral LBPs
        3. Fungal LBPs
        4. Others
      3. APAC Live Biotherapeutic Products And Microbiome CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gastrointestinal Disorders
        2. Oncology
        3. Neurological Disorders
        4. Infectious Diseases
        5. Others
      4. China
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      5. Korea
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      6. Japan
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      7. India
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      8. Australia
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      9. Taiwan
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      10. South East Asia
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      11. Rest of Asia-Pacific
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
    4. Middle East and Africa
      1. Middle East and Africa Live Biotherapeutic Products And Microbiome CDMO Market By Component 2022-2034 (USD MILLION/ Units)
        1. Solution
        2. Services
      2. Middle East and Africa Live Biotherapeutic Products And Microbiome CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Bacterial LBPs
        2. Viral LBPs
        3. Fungal LBPs
        4. Others
      3. Middle East and Africa Live Biotherapeutic Products And Microbiome CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gastrointestinal Disorders
        2. Oncology
        3. Neurological Disorders
        4. Infectious Diseases
        5. Others
      4. UAE
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      5. Turkey
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      6. Saudi Arabia
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      7. South Africa
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      8. Egypt
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      9. Nigeria
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      10. Rest of MEA
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
    5. LATAM
      1. LATAM Live Biotherapeutic Products And Microbiome CDMO Market By Component 2022-2034 (USD MILLION/ Units)
        1. Solution
        2. Services
      2. LATAM Live Biotherapeutic Products And Microbiome CDMO Market By Type 2022-2034 (USD MILLION/ Units)
        1. Bacterial LBPs
        2. Viral LBPs
        3. Fungal LBPs
        4. Others
      3. LATAM Live Biotherapeutic Products And Microbiome CDMO Market By Application 2022-2034 (USD MILLION/ Units)
        1. Gastrointestinal Disorders
        2. Oncology
        3. Neurological Disorders
        4. Infectious Diseases
        5. Others
      4. Brazil
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      5. Mexico
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      6. Argentina
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      7. Chile
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      8. Colombia
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
      9. Rest of LATAM
        1. Solution
        2. Services
        3. Bacterial LBPs
        4. Viral LBPs
        5. Fungal LBPs
        6. Others
        7. Gastrointestinal Disorders
        8. Oncology
        9. Neurological Disorders
        10. Infectious Diseases
        11. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.